Genix Pharmaceuticals Corporation
GENX.V
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -56.56% | 49.54% | -158.95% | -1.33% | 42.18% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -75.00% | -- | -- |
| Total Other Non-Cash Items | 104.52% | -39.29% | 125.05% | 28.33% | -8.68% |
| Change in Net Operating Assets | -96.36% | -64.29% | -89.66% | 736.36% | 230.95% |
| Cash from Operations | -36.78% | 49.77% | 24.32% | 65.97% | 79.81% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 62.34% | -- | -97.36% | -65.67% | -73.76% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 69.44% | -- | 65.25% | -65.59% | -75.06% |
| Foreign Exchange rate Adjustments | -507.69% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -287.50% | -284.48% | 3,022.22% | -60.00% | 300.00% |